红素治疗肌性衰变型1:多中心,随机,双盲,安慰剂控制,第二阶段试验
Masayuki Nakamori1,2, Daisaku Nakatani3, Tomoharu Sato4
1Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
EClinicalMedicine
|February 5, 2024
概括
红素在1型肌性缩症 (DM1) 的第二阶段试验中显示出良好的安全性. 虽然没有统计学意义,但一些生物标志物有所改善,这表明未来研究的潜在有效性.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌性缩症1型 (DM1) 是一种遗传性疾病,由DMPK基因中CTG重复扩张引起.
- 这种扩张导致有毒的RNA和破坏的拼接,导致多系统效应.
- 临床前研究表明,红红素可以降低RNA毒性,并改善DM1小鼠模型中的拼接.
研究的目的:
- 评估红红素在患有DM1的成年患者的安全性和有效性.
- 将有希望的临床前发现转化为临床环境.
- 评估红色素对安全性,耐受性,拼接生物标志物和临床结果的影响.
主要方法:
- 一个多中心,随机,双盲,安慰剂控制的第二阶段试验,涉及30名成年DM1患者.
- 参与者接受安慰剂或红色素 (每天500毫克或800毫克) 24 周.
- 结果包括安全性,耐受性,剪接生物标志物 (MBNL1,CACNA1S),6分钟步行测试,肌肉力量和CK水平.
主要成果:
- 红素是安全的,耐受性很好,有轻度至中度,自我解决的不良事件.
- 肌酸激酶 (CK) 水平在红红素组呈现下降趋势,但没有统计学意义 (p=0.070).
- 与安慰剂相比,在接受红红治疗的组中,在两个拼接生物标志物MBNL1 (p=0.048) 和CACNA1S (p=0.042) 中观察到显著改善.
结论:
- 红素在DM1患者中表现出有利的安全性和耐受性概况.
- 在拼接生物标志物的初步疗效信号需要进一步调查.
- 建议进行更大,更强大的第三期试验,以确认DM1治疗的疗效.
相关概念视频
01:15Myasthenia Gravis: Diagnostic Tests
844
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
844
01:20Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
01:21Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588